• POSC356 Pilot Study for Assessment of Health State Utilities Associated with False-Positive Cancer Screening Results

    Jan 1, 2022, 00:00

  • POSB206 The Early Access Program in Portugal: A Quantitative and Qualitative Analysis

    Jan 1, 2022, 00:00

  • POSB115 Approaches for Modeling Treatment Effect Waning in Markov Cohort Models in Nice Reviews of Non-Oncology Agents

    Jan 1, 2022, 00:00

  • POSA332 Patient Reported Experience Measure for Adult Patients with Sickle Cell Disease (SCD) in Greece

    Jan 1, 2022, 00:00

  • POSB116 Budget Impact Analysis of Pegaspargase in Acute Lymphoblastic Leukemia in Spain

    Jan 1, 2022, 00:00

  • POSC308 Network Meta-Analysis Under Survival Heterogeneity with Long-Term Survival: A Case Study from Adjuvant Treatment of Resected Stage III/IV Melanoma

    Jan 1, 2022, 00:00

  • POSC115 Cost Effectiveness Economic Evaluation of Cefiderocol for the Treatment of Suspected Carbapenem-Resistant Infections in Italy

    Jan 1, 2022, 00:00

  • POSB13 Thirty-Day Readmission in US Hospitalized COVID-19 Patients

    Jan 1, 2022, 00:00

  • POSB266 NICE Published Oncology Recommendations: What Progress Has Been Made During the COVID-19 Era?

    Jan 1, 2022, 00:00

  • POSA276 Review of Efficiency Opinions Published By the Economic and Public Health Assessment Committee (CEESP)

    Jan 1, 2022, 00:00

  • POSC143 Comparison of Model Structures Used in NICE and ICER Cost Effectiveness Evaluations

    Jan 1, 2022, 00:00

  • POSB65 Economic Burden of COPD in the United Kingdom (2021–2040) Estimated with the COPD Health Outcome Policy and Intervention (CHOPIN) Model

    Jan 1, 2022, 00:00

  • POSA341 Proposals for Improving the Management of Age-Related Macular Degeneration for Patients and Healthcare Professionals: Results from the Objetivo Dmae Project

    Jan 1, 2022, 00:00

  • POSA311 Surrogate Outcomes for Overall Survival in Pretreated Non-Small Cell Lung Cancer: Expanding the Prediction Range

    Jan 1, 2022, 00:00

  • POSC284 The Acceptance of Minimal Residual Disease (MRD) as a Clinical Endpoint in Multiple Myeloma (MM): A Targeted Literature Review

    Jan 1, 2022, 00:00

  • POSC41 Cost-Effectiveness Analysis of Remdesivir for the Treatment of COVID-19 Hospitalized Adults in Mexico

    Jan 1, 2022, 00:00

  • POSA182 Progression of Mild Cognitive Impairment Cases to Alzheimer's Disease: Life Study

    Jan 1, 2022, 00:00

  • POSC283 Number Needed to Treat and Incremental Costs per Responder for Biologics and Targeted Synthetic Drugs in Adult Patients with Active Psoriatic Arthritis in the Russian Federation

    Jan 1, 2022, 00:00

  • POSA419 Diabetes Treatment Cost in Lebanon Using a Real-World Dataset from Private Payer

    Jan 1, 2022, 00:00

  • POSB409 Caregiver Absence Time and Payments Due to Sick Leave, Long- and Short-Term Disability and Workers' Compensation for Employees Whose Spouses Have Cancer in the United States

    Jan 1, 2022, 00:00

  • POSA41 Budget Impact Analysis of Lurasidone in the Treatment of Adult Patients with Schizophrenia in Spain

    Jan 1, 2022, 00:00

  • POSB374 Patient and Caregiver Preferences for Treatment Attributes in Type 2 and Non-Ambulatory Type 3 Spinal Muscular Atrophy: A Pan-European Stated Preference Survey

    Jan 1, 2022, 00:00

  • POSC241 Biomarker Guided Treatment in Non-Small Cell Lung Cancer (NSCLC): Adherence to NCCN Guidelines, and Outcomes in a US-Based Population

    Jan 1, 2022, 00:00

  • The Health Value of Kidney Exchange and Altruistic Donation

    Jan 1, 2022, 00:00

  • POSA397 Pharmacoepidemiological Study on the Use of Growth Hormone Therapy in Portuguese Paediatric Patients.

    Jan 1, 2022, 00:00

  • POSA345 Characterising Patient Preferences for Treatment Attributes in Heart Failure with Preserved Ejection Fraction

    Jan 1, 2022, 00:00

  • POSA127 Economic Burden of Adverse Clinical Outcomes Associated with Intraoperative Hypotension in High-Risk Non-Cardiac Surgery in Spain

    Jan 1, 2022, 00:00

  • POSA34 Comparative Efficacy and Safety of Treatment Regimens for Advanced, Recurrent, or Metastatic Endometrial Cancer: A Systematic Review

    Jan 1, 2022, 00:00

  • POSA152 Characterising Patients with Major Depressive Disorder with Moderate-to-High Suicide Intent and Their Healthcare Resource Utilisation in England

    Jan 1, 2022, 00:00

  • POSA344 Willingness-to-Pay and Preferences of Patients Undergoing a Cystoscopy: Results from a Large Survey-Based Study in Spain

    Jan 1, 2022, 00:00

  • POSA315 A Computationally Efficient Alternative Method for Probabilistic One-Way Sensitivity Analysis

    Jan 1, 2022, 00:00

  • P2 Estimation of Metastatic Colorectal Cancer Patients Carrying BRAF Mutation Potentially Eligible to Targeted Therapy: A Real-World Evidence Study in Italy

    Jan 1, 2022, 00:00

  • POSB387 Leveraging Real-World Data for Time-to-Event Endpoints in Clinical Trials

    Jan 1, 2022, 00:00

  • POSA363 Lasting Impacts of the COVID-19 Pandemic on Patients Affected By Chronic Diseases in Europe

    Jan 1, 2022, 00:00

  • POSC128 Healthcare Resource Utilization in Adults Diagnosed with Acute Myeloid Leukemia (AML) in Helsinki and Uusimaa Hospital District

    Jan 1, 2022, 00:00

  • POSA248 Consistency of Metastatic Non-Small Cell Lung Cancer and Renal Cell Carcinoma Treatment Patterns Across Italian Regions

    Jan 1, 2022, 00:00

  • POSC240 Understanding the Patient Journey of Pediatric Patients with Atopic Dermatitis in Portugal: Results from Interviews and an Online Physician Survey

    Jan 1, 2022, 00:00

  • POSB186 Global Clinical, Economic, and Humanistic Burden of Marginal Zone Lymphoma: A Systematic Literature Review

    Jan 1, 2022, 00:00

  • POSC419 Examining the Rate of COVID-19 Breakthrough Infections in Individuals Who Received mRNA Vaccine in the United States

    Jan 1, 2022, 00:00

  • POSA200 Characterization of Atopic Dermatitis Patients Treated in Colombia

    Jan 1, 2022, 00:00

  • POSC317 Multi-Level Network Meta Regression: Some Practical Experiences from an Industry Perspective

    Jan 1, 2022, 00:00

  • POSB37 Real-World Costs of Reintervention in Stenting with Femoropopliteal Artery Revascularization

    Jan 1, 2022, 00:00

  • POSA246 A Real World Evaluation to Describe Resource Use for the Management of Moderate to Severe Atopic Dermatitis in Secondary Care for Children and Adolescents Aged 6 to 17 in the Republic of Ireland

    Jan 1, 2022, 00:00

  • POSC21 Biologicals in the Treatment of Severe Asthma: Effectiveness, Safety and Economic Impact Using Hospital Real-World Data

    Jan 1, 2022, 00:00

  • POSC92 Markov Model Applied to a Cost-Effectiveness Study of a Novel Technology for Patient Stratification with Atrial Fibrillation

    Jan 1, 2022, 00:00

  • POSC297 Assessing and Comparing the Situation of Respiratory Endoscopy in Catalonia in 2019 with Previous Audits and Defining Quality Kpis

    Jan 1, 2022, 00:00

  • POSC54 Health State Utilities of Patients with Chronic Myeloid Leukemia: A Systematic Literature Review

    Jan 1, 2022, 00:00

  • POSB345 Updated 2018 - 2020 Review of Patient-Reported Outcomes in Orphan Drug Labels Approved by the US Food and Drug Administration

    Jan 1, 2022, 00:00

  • POSC160 Economic Evaluation of Using Ribociclib in HER2- Negative Breast Cancer Patients: A Systematic Review of Evidence

    Jan 1, 2022, 00:00

  • POSA74 Accounting for Population Heterogeneity Over-Time in Estimating Costs and Outcomes in Cohort-Based Health-Economic Evaluations

    Jan 1, 2022, 00:00

  • POSC116 Economic Evaluation of Cefiderocol in Patients with Confirmed Carbapenem-Resistant Infections in the Italian Healthcare System

    Jan 1, 2022, 00:00

  • POSA137 Cost-Effectiveness Analysis of a New Anticalcification Treatment Tissue Valve vs. Mechanical Heart Valves in Subgroups of People Aged 55-64 and >65 with Aortic Stenosis (AS) Suitable for Surgical Aortic Valve Replacement (SAVR)

    Jan 1, 2022, 00:00

  • P46 Effective Use of Reconstructed Survival and Comparative Effectiveness Data: A Case Study from Estimating Unreported Subgroup Survival in Advanced Stage Gastrointestinal Cancers

    Jan 1, 2022, 00:00

  • POSC59 Healthcare Expenditures of Older United States Adults with Self-Reported Pain and Functional Limitations: A Cross-Sectional, Retrospective Database Study

    Jan 1, 2022, 00:00

  • POSB151 Brigatinib As a Leading Option to Manage Previously Not Treated Patients with Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer (ALK+ NSCLC) in Portugal

    Jan 1, 2022, 00:00

  • POSC173 The Association Between Physical Activity, Body Mass Index and Health Complaints Among Hungarian School-Aged Children

    Jan 1, 2022, 00:00

  • POSB276 Network Meta-Analyses of Nivolumab Plus Fluoropyrimidine and Platinum Chemotherapy Versus Recommended Treatment Regimens in 1L Gastroesophageal Adenocarcinoma

    Jan 1, 2022, 00:00

  • POSB243 Oncologists’ Preferences for First-Line (1L) Treatment of Locally Advanced/Unresectable or Metastatic Urothelial Carcinoma (aUC)

    Jan 1, 2022, 00:00

  • POSC250 Association Between Iron Therapies and Inflammatory Bowel Disease Progression in Patients with Iron Deficiency Anemia: A Retrospective Real-World Evidence Study in an Italian Setting

    Jan 1, 2022, 00:00

  • POSB120 Economic Assessment of Ribociclib for the Treatment of Postmenopausal Patients with Advanced Breast Cancer HR-Positive, HER2-Negative.

    Jan 1, 2022, 00:00

  • POSC138 The Burden Due to Moderate-to-Severe Paediatric Atopic Dermatitis Treated with Systemic Immunosuppressants on the Healthcare System in England

    Jan 1, 2022, 00:00

  • POSC393 The Clinical and Economic Burden Imposed By Ileostomy Creation: A Danish Registry Study

    Jan 1, 2022, 00:00

  • POSC268 The Benefit Assessment of Gene Therapy Medicines in Germany

    Jan 1, 2022, 00:00

  • POSA355 Pan-European Study on the Management of Medication Adheren A Study Protocol By Cost Action 'Enable' Working Group 1

    Jan 1, 2022, 00:00

  • POSC382 Patient Relevant Criteria of Person-Centered Care for Community-Dwelling People with Dementia: A Formative Qualitative Study to Design a Quantitative Preference Study

    Jan 1, 2022, 00:00

  • POSA219 What Is the Value of Deep-Brain Stimulation in Parkinson's Disease?

    Jan 1, 2022, 00:00

  • POSB413 Demographic Characteristics and Disease Subtypes of Patients with Acute Myeloid Leukemia across Large Community Health Systems in the US

    Jan 1, 2022, 00:00

  • POSA131 Costs of Relapsed/Refractory Acute Myeloid Leukemia (AML) in Colombia

    Jan 1, 2022, 00:00

  • POSB110 Economic Evaluation of Acalabrutinib for Previously-Treated Patients with Mantle Cell Lymphoma in Mexico

    Jan 1, 2022, 00:00

  • POSA273 Systematic Review, Meta-Analysis of Per OS Administered Drugs in Cystic Fibrosis

    Jan 1, 2022, 00:00

  • POSB264 An Analysis of Ultra-Orphan Initial Assessments in Scotland Compared with Other Key European HTA Agencies

    Jan 1, 2022, 00:00

  • POSB357 Health State Utilities for Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

    Jan 1, 2022, 00:00

  • POSA352 The Preferences of Australian Women for the Outcomes of Long-Acting Reversible Contraception (LARC)

    Jan 1, 2022, 00:00

  • POSA2 Clinical Features and Management of COVID 19 in Saudi Arabia

    Jan 1, 2022, 00:00

  • POSA360 Economic Burden of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency in Europe, from the Caregivers Perspective

    Jan 1, 2022, 00:00

  • POSA103 Estimation of the Economic and Social Burden of Pulmonary Arterial Hypertension in Spain

    Jan 1, 2022, 00:00

  • POSA30 Canadian Real-World Experience with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Systemic Anticancer Therapy

    Jan 1, 2022, 00:00

  • POSA225 Comparing the US Drug Development, Pricing, Access, and Reimbursement Strategies for COVID-19 Vaccines as a Potential Model for Novel Oncology Therapies

    Jan 1, 2022, 00:00

  • P60 A New Online Tool for Valuing Health States: Eliciting Personal Utility Functions for the EQ-5D-5L

    Jan 1, 2022, 00:00

  • POSA27 Are Digital Endpoints Being Used To Support Labelling Claims? A Status Check

    Jan 1, 2022, 00:00

  • POSC122 Cost-Effectiveness of ALPHA-2 Adrenergic Agonist (LOFEXIDINE) and Long-Acting Injectables for Treatment of Opioid Use Disorder

    Jan 1, 2022, 00:00

  • POSB91 Comparing Healthcare Costs and Utilization in Osteoarthritis Patients with Different Levels of Treatment-Based Severity: An 18-Year Retrospective Study

    Jan 1, 2022, 00:00

  • POSC296 Whole Blood Processing Systems: An Analysis on the Differences Between Automated Blood Processing System and the Bottom-to-Top Semiautomated Blood Processing System

    Jan 1, 2022, 00:00

  • POSB177 Epidemiological Disease Burden of Other Cataract Based on Routinely Collected Health Insurance Claims DATA

    Jan 1, 2022, 00:00

  • POSA409 Somatic Gene Alteration Testing and Systemic Antineoplastic Treatment Utilization Among Patients with Advanced Non-Small Cell Lung Cancer across Large Community Health Systems in the US

    Jan 1, 2022, 00:00

  • POSB238 Disease Burden of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency: Healthcare Resource Use (HCRU) Overall and by Disease Severity

    Jan 1, 2022, 00:00

  • POSB335 Pilot Investigation of the Short-Term Quality of Life and Socio-Demographic Factors of Men and Women Underwent Total Hip Arthroplasty in Hungary

    Jan 1, 2022, 00:00

  • POSC57 The Costs and Time Associated with the Infusions of PD-1 Inhibitors in Melanoma Patients in Sweden

    Jan 1, 2022, 00:00

  • P52 Surrogate Survival Endpoints: Are They Sufficient to Support Access?

    Jan 1, 2022, 00:00

  • POSB29 Can Predictive Tools and Analytics Foresee Health Outcomes or Identify Patient Subgroups with Higher Risk of Progression in the Management of Inflammatory Bowel Disease? A Systematic Literature Review

    Jan 1, 2022, 00:00

  • POSA3 Comparative Efficacy of Anti-Vascular Endothelial Growth Factor (ANTI-VEGF) Agents for Treatment of Neovascular Age-Related Macular Degeneration (NAMD): A Systematic Review and Network Meta-Analysis

    Jan 1, 2022, 00:00

  • POSA395 Operational Waste Management Model Articulated Between Insurer Health and Pharmaceutical Benefit Manager

    Jan 1, 2022, 00:00

  • POSC380 Socio-Demographic Determinants of the Dermatology Life Quality Index in a Representative Sample of the Hungarian Population

    Jan 1, 2022, 00:00

  • POSA226 Analysis of Requirement of Implantation for Implantable Cardioverter Defibrillator in the Russian Federation

    Jan 1, 2022, 00:00

  • POSB319 Predictive Analytic Techniques and Big Data for Improved Health Outcomes in the Context of Value Based Health Care and Coverage Decisions: A Scoping Review

    Jan 1, 2022, 00:00

  • POSB428 Placebo Response Propensity Scale (PRPS): Implications for Trial Design

    Jan 1, 2022, 00:00

  • POSC253 Analysis of Result of Early Benefit Assessment and Reimbursement Price After Free-Pricing Period in Germany

    Jan 1, 2022, 00:00

  • POSB165 Social and Economic Impacts of Proximal Femur Fracture Surgical Treatment on Geriatric Patients in the Russian Federation

    Jan 1, 2022, 00:00

  • POSA296 Optimizing Healthcare Expenditure for Spinal Cord Stimulation in Italy: Value of Battery Longevity Improvement and a Direct-to-Implant Approach

    Jan 1, 2022, 00:00

  • POSA199 Risk of Cardiovascular Events after Streptococcus Pneumoniae Infections: Life Study

    Jan 1, 2022, 00:00

  • POSA302 The Association Between Progression-Free Survival and Overall Survival in Oncology Trials: A Simulation Exercise

    Jan 1, 2022, 00:00

  • POSB8 Efficacy and Safety Results from Randomized Controlled Trials (RCTS) Evaluating Adjuvant Treatment after Radical Resection (RR) of Muscle Invasive Urothelial Carcinoma (MIUC): A Systematic Literature Review (SLR)

    Jan 1, 2022, 00:00

  • POSC172 The Long-Term Acceptability of COVID-19 Hygiene Measures, for the UK General Population

    Jan 1, 2022, 00:00

  • POSC301 Optimization of a Pre-Defined Algorithm Using Cluster Analysis - Application to a Cohort of Diabetic Patients from the French National Health Data System

    Jan 1, 2022, 00:00

  • POSA376 Health State Utilities and Willingness to Pay in Patients with Coeliac Disease

    Jan 1, 2022, 00:00

  • POSC20 Treatment Patterns and Survival Among Patients With Advanced Renal Cell Cancer: Results of a Nationwide Cohort Study in Denmark

    Jan 1, 2022, 00:00

  • POSA339 Relationships Between Handgrip Strength and Risk of Cardiovascular Disease

    Jan 1, 2022, 00:00

  • POSC233 Frequency of Use of Percutaneous Mechanical Circulatory Support in Germany: IABP, MBP VA-ECMO During 2006 - 2018

    Jan 1, 2022, 00:00

  • POSC428 Identifying African American Male Prostate Cancer Screening Candidates in US Veterans through Family History and BRCA Mutation: A Protocol for an NLP Guided Approach

    Jan 1, 2022, 00:00

  • POSC111 Cost-Minimization Analysis of Bovine and Porcine Bioprosthetic Aortic Valves for the Treatment of Severe Aortic Stenosis in Colombia

    Jan 1, 2022, 00:00

  • POSB70 Systematic Literature Review of Cost and Data Sources for Economic Evaluations in Hypercholesterolaemia and Mixed Dyslipidaemia from a UK Perspective

    Jan 1, 2022, 00:00

  • POSB359 Effect of Dupilumab on Physical and Work-Related Activity in Patients with Moderate-to-Severe Asthma: Liberty Asthma QUEST

    Jan 1, 2022, 00:00

  • POSB300 Ontology-Based Text Mining in Scientific Literature

    Jan 1, 2022, 00:00

  • POSB417 Predicting Medical and Pharmacy Spend on Specialty Drugs By Employer Groups in the United States

    Jan 1, 2022, 00:00

  • POSA401 Impact of COVID-19 on Surgical Activity: Experience from a French University Teaching Hospital

    Jan 1, 2022, 00:00

  • POSC245 Physician Preferences in Prescribing Oral Anticoagulation Therapy in Elderly Non-Valvular Atrial Fibrillation Patients with Comorbidities: A Clinical Vignette Study

    Jan 1, 2022, 00:00

  • POSA328 Treatment Preferences in Fabry Disease: A Discrete Choice Experiment in Denmark and the UK

    Jan 1, 2022, 00:00

  • POSA290 Prevalence of Stone Disease and Procedure Trends Among a US Commercial Population

    Jan 1, 2022, 00:00

  • POSA265 HTA Requirements for Advanced Therapy Medicinal Products (ATMPS) in Germany

    Jan 1, 2022, 00:00

  • POSB365 A Prospective Observational Study to Determine the Safety and Efficacy of Quetiapine in Delirium Patients

    Jan 1, 2022, 00:00

  • POSA350 Effect of Filgotinib on EQ-5D-5L and Work Productivity and Activity Impairment Among Patients with Ulcerative Colitis: Results from the Phase 2B/3 Selection Trial

    Jan 1, 2022, 00:00

  • POSC242 Indication Trends in Robot-Assisted Prostatectomy in Japan

    Jan 1, 2022, 00:00

  • POSB112 Health Care Resource Use of Transthyretin Amyloid Cardiomyopathy in Sweden

    Jan 1, 2022, 00:00

  • POSC137 Absence Time and Payments Due to Sick Leave, Long- and Short-Term Disability and Workers' Compensation for Employees with Skin Conditions in the United States

    Jan 1, 2022, 00:00

  • P20 Evaluating Preferences and the Effect of Altruism on COVID-19 Vaccine Decisions: A Discrete Choice Experiment

    Jan 1, 2022, 00:00

  • POSC189 A Patient Registry-Based Cross-Sectional Study of the Burden and Management of Comorbid Psoriatic Arthritis (PsA) in Patients with Systemic Lupus Erythematosus (SLE)

    Jan 1, 2022, 00:00

  • POSA403 Emergency Room Visits, Lost Time and Productivity Costs in Employees with Coronary Artery Disease Are Impacted By Medication Adherence

    Jan 1, 2022, 00:00

  • POSC2 A Case Study: Evaluation of the Infantile Neuroaxonal Dystrophy Rating Scale (INAD-RS)

    Jan 1, 2022, 00:00

  • POSA185 Epidemiological Disease Burden of Hypertensive Heart Disease with Heart Failure Based on Routinely Collected Health Insurance Claims Data

    Jan 1, 2022, 00:00

  • POSB307 Impact of Antidiabetic Treatment on Renal Function in Diabetics with Chronic Renal Failure

    Jan 1, 2022, 00:00

  • P75 Use of Electronic Health Records to Understand the Disease Progression in Lupus Nephritis (LN)

    Jan 1, 2022, 00:00

  • POSC224 Drug Supply Chain Disruption: Retrospective Analysis of Substitution Procurement Agreements in a University Hospital Structure

    Jan 1, 2022, 00:00

  • POSA230 Augmentation of Appropriate Antibiotic Therapy in Surgical Care: A Preceding Initiative for Handshake Antibiotic Stewardship Program in India

    Jan 1, 2022, 00:00

  • POSB426 Long-Term Time-Varying Survival Treatment Effect in the Presence of Scheduled Switch from Placebo to Active Treatment

    Jan 1, 2022, 00:00

  • POSB258 Evaluation of the Current Impact of Indirect Treatment Comparisons (ITCS) to Support Health Technology Assessments (HTAS) in Rare Diseases

    Jan 1, 2022, 00:00

  • POSB407 The Caregiver Burden Associated with Haemophilia, Real World Evidence from the 'Cost of Haemophilia in Men: A Socioeconomic Survey' (CHESS) II Study

    Jan 1, 2022, 00:00

  • POSB425 Methodological Challenges to Coronavirus Disease (COVID-19) Evidence Generation to Inform Health Technology Assessment (HTA)

    Jan 1, 2022, 00:00

  • POSA429 Safety-Research Database for Economic Evaluations (SRD-EE)

    Jan 1, 2022, 00:00

  • POSA191 Transmission Control Outcomes for Tuberculosis in Polar Regions: A Review

    Jan 1, 2022, 00:00

  • POSA305 A Systematic Comparison of the Meta-Analysis Software Landscape and Validation of Metaxact for Meta-Analysis of Sparse Outcomes

    Jan 1, 2022, 00:00

  • POSA180 Real-World Therapeutic Patterns of Patients in Haemodialysis Affected By Chronic Kidney Disease-Associated Pruritus: An Italian Administrative Database Analysis

    Jan 1, 2022, 00:00

  • Issues with Health Technology Assessment of Specialised Technologies

    Jan 1, 2022, 00:00

  • POSC133 Use of Expert Elicitation to Extrapolate Observed Intermediate Clinical Trial Outcomes to Clinically Meaningful Long-Term Outcomes for Use in Health Technology Assessments: A Case Study in a Rare, Lifelong Disease

    Jan 1, 2022, 00:00

  • POSA148 Cost Effectiveness of Ofatumumab in Comparison with Other Disease Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada

    Jan 1, 2022, 00:00

  • POSA228 Treatment Patterns of Atopic Dermatitis Patients in Sweden

    Jan 1, 2022, 00:00

  • POSC340 Health-Related Quality of Life Among Refractory/Relapsed B-Cell Precursor Acute Lymphoblastic Leukemia Patients Treated with KTE-X19: Phase 2 Results from Zuma-3 Trial

    Jan 1, 2022, 00:00

  • POSB107 A Retrospective Observational Study of Ibrutinib in Real-Life Settings in France, Using the SNDS Database (OSIRIS)

    Jan 1, 2022, 00:00

  • POSA358 The Impact of Patient-Reported Outcomes in Market Access: A Literature Review, Regulatory Evidence Assessment Framework and Study

    Jan 1, 2022, 00:00

  • POSB79 Annual Health Insurance Treatment Cost of Mental and Behavioural Disorders Due to Use of Tobacco Based on Routinely Collected Financing Data

    Jan 1, 2022, 00:00

  • Methodological Developments in Survival Analytic Methods: to Inform Cost-Effectiveness Models

    Jan 1, 2022, 00:00

  • POSB259 Immuno-Oncology Treatments: Key Factors Influencing NICE Approval, 2011-2020

    Jan 1, 2022, 00:00

  • POSA196 Economic Burden Associated with Advanced Prostate Cancer in Mexico

    Jan 1, 2022, 00:00

  • POSC12 Clinical Presentation of Cutaneous Adverse Drug Reaction with Their Frequency in Tertiary Care Hospital, Bangalore : An Observational Study

    Jan 1, 2022, 00:00

  • POSA172 How to Optimize COVID-19 Vaccination Considering Limited Vaccination Capacities: A Decision-Analytic Framework and Modeling Study

    Jan 1, 2022, 00:00

  • POSA72 Cost-Effectiveness Analysis of the Helicopter Emergency Medical Services for Stroke Patients in Austria

    Jan 1, 2022, 00:00

  • POSB192 Public Health and Economic Impact of Influenza Immunization by Pharmacists: A Systematic Literature Review and Analysis of the French Experience

    Jan 1, 2022, 00:00

  • POSB337 Comparison Between Thoracic Spine Deformities and Impingement Syndrome Among Volleyball Players in Different Age Groups

    Jan 1, 2022, 00:00

  • Epidemiology Public Health

    Jan 1, 2022, 00:00

  • POSC202 Estimated Migraine Patient Population in England Progressing Beyond First-Line Acute Management

    Jan 1, 2022, 00:00

  • POSC204 Drug-Drug Interaction Databases: Sensitivity and Specificity to Detect Manifest Drug-Drug Interactions, Reliability Ratings and Management Strategies of Potential Drug-Drug Interactions

    Jan 1, 2022, 00:00

  • POSC416 The Cost of Haemophilia in Men - A Socioeconomic Survey (CHESS) II Study: Methods: and Key Results

    Jan 1, 2022, 00:00

  • POSA207 Expert Consensus on Payment Models for Multi-Indication Therapies

    Jan 1, 2022, 00:00

  • POSB119 Economic Impact of Once-Daily MeltDose Extended-Release Tacrolimus (LCP-TAC) in Patients with Kidney or Liver Transplantation in Spain

    Jan 1, 2022, 00:00

  • POSA141 Cost Effectiveness Analysis of Pembrolizumab Monotherapy in Advanced PD-L1 ≥50% Non-Small Cell Lung Cancer (NSCLC) in the Irish Setting

    Jan 1, 2022, 00:00

  • POSB219 A Framework for Gene Therapy Disease Area Targeting

    Jan 1, 2022, 00:00

  • POSA6 Use of Real-World Evidence to Evaluate Infliximab Biosimilars: A Scoping Review

    Jan 1, 2022, 00:00

  • POSC217 Hypertension in Pregnancy, Preeclampsia - Analysis of Complications and Cost of Therapy in Ukraine

    Jan 1, 2022, 00:00

  • POSA217 The Reform of the French Compassionate Use Program : The State and Perspective Before the Change

    Jan 1, 2022, 00:00

  • POSB211 Is an Early Access Program for an Oncology Drug an Asset in the French Pricing and Reimbursement Pathway?

    Jan 1, 2022, 00:00

  • POSB23 Tafasitamab Plus Lenalidomide (T-L) Versus Standard of Care (SoC) Including 3 Rituximab-Based Treatments or Lenalidomide Monotherapy in Patients with Non-Transplant Eligible Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NTE R ...

    Jan 1, 2022, 00:00

  • POSA201 Utilization of Health Care Resources and Sick Leave in Osteoarthritis

    Jan 1, 2022, 00:00

  • POSA234 The Value of a Large Care Network in Delivering Continuity of Care to Clinically Extremely Vulnerable People During a Global Pandemic: A UK Case Study

    Jan 1, 2022, 00:00

  • POSB280 Review of Real-World Data Use in French Economic and Public Health Assessment Committee's (CEESP) Efficiency Opinions for Anticancer Drugs

    Jan 1, 2022, 00:00

  • POSB430 Elicitation of Health State Utilities Associated with Varying Severities of Dry Eye Disease

    Jan 1, 2022, 00:00

  • POSA120 Healthcare Resource Utilization in Patients with Painful Diabetic Neuropathy Treated with 10-Khz Spinal Cord Stimulation: Results from a Randomized Controlled Trial

    Jan 1, 2022, 00:00

  • POSA144 Budget Impact Analysis of Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia: Implications for Six Geographical States of the United States

    Jan 1, 2022, 00:00

  • POSB49 Cost Effectiveness Model of Atezolizumab Plus Bevacizumab in Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) in French Setting

    Jan 1, 2022, 00:00

  • POSC405 Absence Time and Payments Due to Sick Leave, Long- and Short-Term Disability and Workers' Compensation for Employees with Musculoskeletal Conditions in the United States

    Jan 1, 2022, 00:00

  • POSC251 A Comparison of the Reimbursement of Digital Therapeutics in France, Germany and the UK

    Jan 1, 2022, 00:00

  • POSA286 Early Experience with Health Technology Assessments for COVID-19 Treatments

    Jan 1, 2022, 00:00

  • POSB223 Impact of the COVID-19 Pandemic on Influenza Vaccination Policies

    Jan 1, 2022, 00:00

  • POSA53 The Cost-Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease and Heart Failure in the UK

    Jan 1, 2022, 00:00

  • POSB420 Diabetes Treatment Cost in KSA Using a Real-World Dataset from Private Payer

    Jan 1, 2022, 00:00

  • P19 Assessing Heterogeneity in MAR: Methods and Models Beyond DCE

    Jan 1, 2022, 00:00

  • POSB328 Barriers and Enablers for Adherence to Antiretroviral Therapy Among People Living with HIV/AIDS in the Era of COVID-19: A Qualitative Experience from a Low Middle-Income Country

    Jan 1, 2022, 00:00

  • POSA109 The Impact of Improving the Current Approach to Chronic Obstructive Pulmonary Disease Within the Spanish National Health System: A Social Return on Investment Analysis

    Jan 1, 2022, 00:00

  • POSC61 Cost-Effectiveness of ROS1-Testing Strategy Compared to a NO-ROS1-Testing Strategy in Advanced NSCLC in Spain

    Jan 1, 2022, 00:00

  • POSB26 Real-World Effectiveness of Fremanezumab Treatment for Reducing Monthly Migraine and Headache Days in US Patients Having Different Numbers of PRIOR Migraine Preventive Treatment Failures

    Jan 1, 2022, 00:00

  • POSB122 Healthcare Resource Use of People Who Use Illicit Opioids in England: A Retrospective Cohort Study Using Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES)

    Jan 1, 2022, 00:00

  • POSA292 MSCopilot® as a Digital Tool to Collect Patients’ Insights in Health Economics Research in Multiple Sclerosis

    Jan 1, 2022, 00:00

  • POSA346 Differential Burden in Psoriasis Considering Patient-Reported Severity: Results from the National Health and Wellness Survey

    Jan 1, 2022, 00:00

  • POSA105 Cost Consequence Analysis of Open Surgery or Endovascular Treatment of Patients with Abdominal Aortic Aneurysm: The Case of University General Hospital of Heraklion, Greece

    Jan 1, 2022, 00:00

  • POSC229 Headache Clinical Care Pathway: From Process Mapping to Suggestions of Improvement

    Jan 1, 2022, 00:00

  • POSA95 Exploring the Role of Response to Treatment in Oncology Technology Appraisals

    Jan 1, 2022, 00:00

  • POSA347 An Evaluation of the Economic Burden and Quality of Life for Non-Small Cell Lung Cancer Patients with Exon 20 Insertions in China

    Jan 1, 2022, 00:00

  • POSC368 Understanding the Impact of Chronic Spontaneous Urticaria (CSU) and What Is Most Important to Patients — Results from Qualitative Patient Interviews

    Jan 1, 2022, 00:00

  • POSB244 Regional Variation in Uptake of Recommended Cancer Treatments in England (2018-2020) - An Osimertinib Case Study

    Jan 1, 2022, 00:00

  • POSC170 Decreased Opioid Use in Migraine Patients Following Rimegepant Initiation: A Real-World Analysis

    Jan 1, 2022, 00:00

  • POSB146 Economic Burden of Migraine in Turkey

    Jan 1, 2022, 00:00

  • POSA51 Economic Burden of Anxiety Severity in a General Population of US Adults Based on National Health and Wellness Survey (NHWS)

    Jan 1, 2022, 00:00

  • POSC252 Current Level of Patient Engagement in HTA Agencies

    Jan 1, 2022, 00:00

  • POSC51 Optimizing Inhaler Technique in Asthma with Digital Health Technology: An Economic Evaluation

    Jan 1, 2022, 00:00

  • POSC246 The Supply Chain of CAR T Cell Therapy: A Systematic Literature Review

    Jan 1, 2022, 00:00

  • POSA348 Evaluating Real-World Health-Related Quality of Life in a Survey of Patients With Advanced Renal Cell Carcinoma Receiving First-Line Treatment in the US

    Jan 1, 2022, 00:00

  • POSA86 Annual Health Insurance Treatment Cost of Malignant Neoplasm of Oropharynx Based on Routinely Collected Financing Data

    Jan 1, 2022, 00:00

  • POSA102 Burden of Disease and Cost of Illness of Spinal Muscular Atrophy in Portugal

    Jan 1, 2022, 00:00

  • POSA416 Treatment Adherence As a Cost Determinant in Patients with Tuberculosis

    Jan 1, 2022, 00:00

  • POSA63 Direct Costs of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in Latvia

    Jan 1, 2022, 00:00

  • POSC7 Work Productivity and Activity Impairment for Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 AND CIMPASI-2)

    Jan 1, 2022, 00:00

  • POSC190 Hospital Utilization for Elderly Patients Diagnosed with Respiratory Syncytial Virus (RSV) Versus Influenza in the US

    Jan 1, 2022, 00:00

  • POSC373 Use of Aids, Assistive Devices and Adaptations by Individuals with Fibrodysplasia Ossificans Progressiva (FOP): 36-Month Results from a Global Natural History Study

    Jan 1, 2022, 00:00

  • POSA236 Real-World Treatment (Tx) Characteristics for Advanced Non-Small Cell Lung Cancer (aNSCLC) Without Actionable Mutations After Introduction of Immune Checkpoint Inhibitors (ICIs) in EU4 and UK

    Jan 1, 2022, 00:00

  • POSC162 Cost Effectiveness Analysis of Nivolumab Plus Ipilimumab Therapy in Patients with Advanced Non-Small Cell Lung Cancer in Japan

    Jan 1, 2022, 00:00

  • POSB27 Results of Self-Reported EHR COVID Screenings Among Community Oncology Patients

    Jan 1, 2022, 00:00

  • POSA283 Differential Appraisal of Functional Outcome Measures by Health Technology Assessment (HTA) Agencies When Reviewing Therapies for Rare Muscular, Skeletal and Neurodegenerative Disorders

    Jan 1, 2022, 00:00

  • POSC105 Economic Evaluation of the Pediatric Immunization Program in Belgium

    Jan 1, 2022, 00:00

  • POSA93 Economic Evaluation of Fluoride Varnish Application in Iranian Schools

    Jan 1, 2022, 00:00

  • POSC321 Estimating Long-Term Survivorship Rates for Previously Untreated Intermediate or Poor (I/P) Risk Advanced Renal Cell Carcinoma (ARCC) Patients Treated with Nivolumab Plus Ipilimumab (NIVO+IPI): Analyses from the CheckMate 214 Trial

    Jan 1, 2022, 00:00

  • POSA179 Global Incidence and Survival of Acute Myeloid Leukemia with 20-29% Blasts: A Systematic Literature Review

    Jan 1, 2022, 00:00

  • POSB404 Therapeutic Management of Multiple Myeloma and Healthcare Resource Assessment By Matching the Emmy Cohort to the Data of the National Health Data System (SNDS) in France

    Jan 1, 2022, 00:00

  • POSB392 Understanding the Secondary Care Characteristics and Pathways of Multiple Myeloma Patients Who Reach Second-Line Therapy Using the Hospital Episode Statistics (HES) Database

    Jan 1, 2022, 00:00

  • POSB262 Does Trial Blinding Impact Reimbursement Decisions in Lung Cancer?

    Jan 1, 2022, 00:00

  • POSC26 Preferences Toward Attributes of Disease-Modifying Therapies: The Role of Nurses in Multiple Sclerosis Care (DECISIONS-MS STUDY)

    Jan 1, 2022, 00:00

  • POSA238 Hospital Length of Stay and Antibiotic Prescription Practices for Patients Diagnosed with Gram Negative Infections - Evidence from Hospitals in Romania

    Jan 1, 2022, 00:00

  • POSC397 Portuguese Clinical Practice in the Treatment of Metastatic Hormone-Sensitive Prostate Cancer

    Jan 1, 2022, 00:00

  • POSB198 Incidence of Gastrointestinal Stromal Tumour in Europe: A Systematic Literature Review

    Jan 1, 2022, 00:00

  • POSB294 Delay in Percutaneous Nephrolithotomy and Healthcare Utilization Among Patients with a Stent Placement and Stone Disease

    Jan 1, 2022, 00:00

  • POSC37 Economic Cost of Treatment in Canada: A Multi-Centre, Retrospective Study

    Jan 1, 2022, 00:00

  • POSA31 Systematic Literature Review of NMAS of Biological Treatments Including Ustekinumab in Ulcerative Colitis

    Jan 1, 2022, 00:00

  • POSA49 Projecting the Long-Term Benefits of Venetoclax Combination Therapies for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy: An Assessment of Net Health Benefit

    Jan 1, 2022, 00:00

  • POSB33 Comorbidities, Oxygen Therapy Use and Rehospitalization in US Patients with Severe COVID-19

    Jan 1, 2022, 00:00

  • POSB69 Incremental Costs Analysis of Prematurity in Hungary

    Jan 1, 2022, 00:00

  • POSA82 Cost-Effectiveness of Preventive Intervention for Prediabetes in Japan

    Jan 1, 2022, 00:00

  • POSC13 Assessment of Causality, Severity and Preventability of Class of Drugs Causing Cutaneous Adverse Drug Reaction in Tertiary Care Hospital, Bangalore; An Observational Study

    Jan 1, 2022, 00:00

  • POSB21 Monoclonal Antibodies in the Treatment of Persistent, Uncontrolled Eosinophilic Asthma: Systematic Review, Meta-Analysis and Indirect Comparison

    Jan 1, 2022, 00:00

  • POSB405 Data Governance for Rwd/E Management: Optimising Its Use in HTA and Decision-Making

    Jan 1, 2022, 00:00

  • POSC415 Economic and Health-Related Quality of Life Data across Baseline Fix Expression Levels in People with Haemophilia B: An Analysis Using the Factor Expression Study

    Jan 1, 2022, 00:00

  • POSA220 Different Willingness to Pay for Curative Therapies in Fran A Cost per Cure Analysis of Medicines in Different Therapeutic Areas

    Jan 1, 2022, 00:00

  • POSC1 The Influence of Diabetic History in the Prognosis of Hospitalized COVID-19 Patients: A Prospective Observational Study

    Jan 1, 2022, 00:00

  • POSC345 Qualitative Literature and Instrument Review to Develop a Clinical Outcome Assessment (COA) Measurement Strategy for Use in Amblyopia Studies

    Jan 1, 2022, 00:00

  • POSA400 Open-Source Technology Stack for Creating Registries Seeding Interoperable Data Via Rest and Graphql API

    Jan 1, 2022, 00:00

  • POSB384 A Systematic Literature Review of Economic Evidence in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer

    Jan 1, 2022, 00:00

  • POSA75 Systematic Review of Economic Evaluations on Stereotactic Ablative Radiotherapy for the Treatment of Early-Stage Non-Small Cell Lung Cancer

    Jan 1, 2022, 00:00

  • P62 The Impact of the COVID-19 Pandemic on the Quality of Life of Patients with Melanoma – Findings from a UK Melanoma Registry

    Jan 1, 2022, 00:00

  • POSC25 Comparative Efficacy of Abobotulinumtoxina for the Treatment of Refractory Neurogenic Detrusor Overactivity: An Indirect Treatment Comparison

    Jan 1, 2022, 00:00

  • POSA166 Cost-Effectiveness of Using Dapagliflozin in the Treatment of Heart Failure with Reduced Ejection Fraction: A Pharmacoeconomic Model Analysis

    Jan 1, 2022, 00:00

  • POSB113 Machine Learning Can Facilitate More Efficient Health Economic Literature Synthesis by Accurately Extracting Economic Data from Published Abstracts

    Jan 1, 2022, 00:00

  • POSC311 The Methodological Quality of Retrospective Observational Studies to Evaluate Glucose Monitoring Systems in Diabetes Patients: A Systematic Review

    Jan 1, 2022, 00:00

  • POSB9 Short- and Long-Term Performance of Mechanical Versus Biological Prostheses for Aortic Valve Replacement in Patients with Severe Symptomatic Aortic Stenosis over 65 Years

    Jan 1, 2022, 00:00

  • P27 Vaccination Coverage Trends for Hepatitis B in Infants from the Brazilian and Colombian Expanded Immunization Program: A Real-World Analysis of COVID-19 Pandemic Impact

    Jan 1, 2022, 00:00

  • POSB83 Annual Health Insurance Treatment Cost of Non-Insulin-Dependent Diabetes with Renal Complications Based on Routinely Collected Financing Data

    Jan 1, 2022, 00:00

  • POSA261 Systematic Review with Network Meta-Analysis and Multicriteria Acceptability Analyses on the Effects of Systemic Antifungal Agents for Candidemia

    Jan 1, 2022, 00:00

  • POSA55 Optimizing Inhaler Technique in COPD with Digital Health Technology: An Economic Evaluation

    Jan 1, 2022, 00:00

  • POSA125 Comparing Healthcare Cost Among Empagliflozin, DPP-4 Inhibitors and GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus: A German Claims Data Analysis

    Jan 1, 2022, 00:00

  • POSC14 Frequency of Complications in a Cohort of Patients Diagnosed with Hemophilia Undergoing Prophylactic Treatment at a Health Care Institution in Colombia: A Retrospective Non-Interventional Study

    Jan 1, 2022, 00:00

  • POSC18 The Real-World Clinical Effectiveness of GLP-1 Receptor Agonist Liraglutide Among Patients with Type 2 Diabetes in China: Based on Existing Healthcare Data

    Jan 1, 2022, 00:00

  • P58 EQ-5D-5L Population Norms for Italy

    Jan 1, 2022, 00:00

  • POSA417 Trends of Oral Anticoagulant Use and the Predictors of Initiation Choice between Men and Women with Atrial Fibrillation and Discharged from Hospital to the Community

    Jan 1, 2022, 00:00

  • POSA133 Cost-Effectiveness of Dapagliflozin for the Treatment of Heart Failure with Reduced Ejection Fraction: Analyses from the Perspectives of France and the United States

    Jan 1, 2022, 00:00

  • POSB87 Carbon Footprint Impact of Breezhaler® Dry Powder Inhaler for Asthma: An Analysis in UK and Italy

    Jan 1, 2022, 00:00

  • POSC131 Events Avoided and Cost Savings Associated with the Use of Intravenous Ferric Carboxymaltose for the Treatment of Iron Deficiency in Patients Stabilized after an Acute Heart Failure Episode with Reduced Ejection Fraction in the UK

    Jan 1, 2022, 00:00

  • POSC286 Methodological Quality and Transferability of Cancer Costs within the MENA Region: A Systematic Review and Secondary Analysis of Published Data

    Jan 1, 2022, 00:00

  • P43 A Case Study and Simulation to Compare Different Indirect Treatment Comparison Methods Under Varying Access to Individual Patient Data

    Jan 1, 2022, 00:00

  • POSC67 Vaccination Budget Trends in Bulgaria for 2020-2024

    Jan 1, 2022, 00:00

  • POSA164 Cost Minimization and Budget Impact Analysis of Viscosupplementation with Hylan G-F 20 for the Treatment of Knee Osteoarthrosis from the Perspective of the Public Sector in El Salvador and Panama

    Jan 1, 2022, 00:00

  • POSC265 The Use of Glycated Albumin for Glycaemic Control in Diabetic Patients with Chronic Kidney Disease: Preliminary Results from an Italian HTA

    Jan 1, 2022, 00:00

  • POSA211 Are Orphan Drugs in France Priced According to International Prices and Which Factors Could Influence the Negotiated Prices?

    Jan 1, 2022, 00:00

  • POSB127 Cost-Comparison of HBA1C reduction with Gliclazide-Modified Release or Sitaglipltin in Patients with Uncontrolled Type 2 Diabetes after Metformin Monotherapy

    Jan 1, 2022, 00:00

  • POSB304 Quo Vadis Hyt: A Comparison of Hyt and Qalys in HER2+ Breast Cancer

    Jan 1, 2022, 00:00

  • POSB195 Predicting New Mental Health Cases Pre- vs. Post-COVID-19: A Comparison of Medical-Only and Integrated Data

    Jan 1, 2022, 00:00

  • POSC239 Healthcare Resource and Financial Implications of an Environmentally Driven Switch in Respiratory Inhaler Use in the English NHS

    Jan 1, 2022, 00:00

  • POSB343 Living with Distal Renal Tubular Acidosis (DRTA): Qualitative Research with Patients, and Caregivers, and Nephrologists

    Jan 1, 2022, 00:00

  • P54 Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis versus Standard Prophylaxis in Adult Patients with Severe Hemophilia A in China

    Jan 1, 2022, 00:00

  • POSB59 Potential Savings on Medication and Hospitalization Costs for Intensive Home Haemodialysis: An Italian Perspective

    Jan 1, 2022, 00:00

  • POSA124 New Therapies in Huntington's Disease (HD): Challenges in Modelling for Health Economic Evaluations

    Jan 1, 2022, 00:00

  • POSA280 Using Artificial Intelligence and Machine Learning to Inform Evidence Development for Optimising HTA Outcomes in Europe

    Jan 1, 2022, 00:00

  • POSA222 Critical Reflections on Reimbursement and Access of Advanced Therapies

    Jan 1, 2022, 00:00

  • POSB379 Measurement Properties of DLQI, DLQI-R and Skindex-16: A Comparative Study

    Jan 1, 2022, 00:00

  • POSA277 Implemetation of HTA in Decision-Making Process of Selecting Essential Medicines in Ukraine

    Jan 1, 2022, 00:00

  • POSB342 Time Until Definitive Deterioration (TUDD) in Patient Reported Outcomes (PROS) in a Phase 3 Trial for Ripretinib in 4L Patients with Gastrointestinal Stromal Tumour (GIST)

    Jan 1, 2022, 00:00

  • POSA106 Early-Stage Economic Evaluation for the Fit for Labour Test: A Clinical Decision Support Tool for Labour Management

    Jan 1, 2022, 00:00

  • POSC282 Development of a Value Framework to Conclude on Clinical Added Benefit in Hungary

    Jan 1, 2022, 00:00

  • POSA359 Caring for an Individual with Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency: Results from a Caregiver Questionnaire

    Jan 1, 2022, 00:00

  • POSC337 Efficiency of Using Franklin Balls Among Equestrians - Controlled Study

    Jan 1, 2022, 00:00

  • POSA159 Cost-Effectiveness of Netupitant/Palonosetron in the Treatment of Chemotherapy-Induced Nausea and Vomiting in the UK

    Jan 1, 2022, 00:00

  • POSA408 Direct and Indirect Costs Associated with Multiple Myeloma in Slovakia: 5 Years Overview

    Jan 1, 2022, 00:00

  • POSB160 Cost-Effectiveness of Dapagliflozin Compared to DPP-4 Inhibitors as Combination Therapy with Metformin in the Treatment of Type 2 Diabetes Mellitus without Established Cardiovascular Disease in Colombia

    Jan 1, 2022, 00:00

  • POSC101 Healthcare Resource Utilization and Costs in Patients with Cervical Dystonia

    Jan 1, 2022, 00:00

  • POSB199 Prevalence of Prurigo Nodularis in the Regional Area of Brittany (France): Estimation by Matching Two Databases

    Jan 1, 2022, 00:00

  • POSB143 The Financial Burden of Surgically Managing Chronic Rhinosinusitis with Nasal Polyposis in England

    Jan 1, 2022, 00:00

  • POSC279 The Impact of a Reassessment Due to New Scientific Findings on the Additional Benefit and on the Reimbursed Price of Pharmaceutical Products According to §35A Sgb V in Germany

    Jan 1, 2022, 00:00

  • Reevaluating the Evidence for Intensive Postoperative Extracolonic Surveillance for Nonmetastatic Colorectal Cancer

    Jan 1, 2022, 00:00

  • POSB50 A Cost-Effectiveness Analysis of Rivaroxaban in Combination with Acetylsalicylic Acid (ASA) in Adult Patients with Coronary Artery Disease (CAD) or Symptomatic Peripheral Artery Disease (PAD) at High Risk of Ischaemic Events

    Jan 1, 2022, 00:00

  • POSC215 Assessment of Tender Adjudication Criteria Among European and Leading Emerging Markets

    Jan 1, 2022, 00:00

  • POSB375 Validation Assessment of a Pain Interference Questionnaire Among Student Pharmacists at a United States University

    Jan 1, 2022, 00:00

  • POSB385 Use of Healthcare Resources and Cost Associated Related to Juvenile Idiopathic Arthritis in Spain: The Itaca-or Real-World Study

    Jan 1, 2022, 00:00

  • POSA134 Evaluating the Economic Effects of Flexible Radionuclide Delivery Timing and Same-Day Work-up and Radioembolization in Patients with Unresectable Liver Tumors Undergoing Selective Internal Radiation Therapy

    Jan 1, 2022, 00:00

  • POSB161 Cost-Effectiveness of Dapagliflozin Plus Standard Treatment Compared to Standard Treatment for the Management of Heart Failure with Reduced Ejection Fraction in Colombia

    Jan 1, 2022, 00:00

  • POSA259 A Multi-Criteria Decision Analysis (MCDA) Tool for Purchasing Off-Patent Oncology Drugs in Egypt

    Jan 1, 2022, 00:00

  • POSB291 A Review of Nice Medtech Innovation Briefings (MIBS) of Digital Health Technologies

    Jan 1, 2022, 00:00

  • POSB189 Mental Health in COVID Times: A Quasi-Experimental Analysis of the Impact of Lockdown Measures on Mental Healthcare Use in Germany

    Jan 1, 2022, 00:00

  • POSB156 Cost-Utility Analysis of Crizanlizumab and Hydroxyurea in Preventing Vaso-Occlusive Events in Patients with Sickle-Cell Disease: A Lifetime Model from a Payer's and Societal Perspectives

    Jan 1, 2022, 00:00

  • POSB105 Budget Impact Analysis of Introduction of Subcutaneous Infliximab in France from a Payer Perspective

    Jan 1, 2022, 00:00

  • POSA94 Risk Factors and Economic Burden of Postoperative Anastomotic Leakage Related Events in Patients Who Underwent Surgeries for Colorectal Cancer

    Jan 1, 2022, 00:00

  • POSB309 Assessing the Validity of Median Time-to-Event Meta-Analysis Using Weighted Median and Median of Medians Approaches: A Simulation Study

    Jan 1, 2022, 00:00

  • POSB331 The Examination of Effectiveness of the Education of Exercise Techniques and Training Methods: in Weight Training

    Jan 1, 2022, 00:00

  • POSC47 The Cost-Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease and Heart Failure in Ireland

    Jan 1, 2022, 00:00

  • POSC349 Is Delayed Recall Affected By Anxiety in a Memory-Impaired Clinic Population?

    Jan 1, 2022, 00:00

  • POSA140 Work Productivity and Activity Impairment of Caregivers of Huntington's Disease Patients in the US and EU5: Evidence from the Huntington's Disease Burden of Illness Study (HDBOI)

    Jan 1, 2022, 00:00

  • POSB84 Annual Health Insurance Treatment Cost of Malignant Neoplasm of Larynx Based on Routinely Collected Financing Data

    Jan 1, 2022, 00:00

  • Disclosure Information

    Jan 1, 2022, 00:00

  • POSB41 Real-World Assessment of Healthcare Resource Utilisation and Direct Medical Costs in Patients with COPD Receiving ICS/LABA Therapy in England

    Jan 1, 2022, 00:00

  • POSC163 Cost-Utility Analysis of Empagliflozin in Chronic Heart Failure with Reduced Ejection Fraction: A UK Healthcare System Perspective

    Jan 1, 2022, 00:00

  • POSC205 A European Perspective on Challenges and Opportunities for Smart Pens in Diabetes Care

    Jan 1, 2022, 00:00

  • POSA195 Assessment of Consumption of Antidepressant Drugs in Ukraine in 2015-2019

    Jan 1, 2022, 00:00

  • P66 Epidemiology of Non-Small Cell Lung Cancer (NSCLC) by Histology and Disease Stage in Western Europe (WE): Population-Level Projections 2021-2026

    Jan 1, 2022, 00:00

  • POSC113 Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in the Treatment of HER2-Positive Breast Cancer (HER2+ BC) Patients in Italy: A Budget Impact Analysis

    Jan 1, 2022, 00:00

  • POSC114 Cost-Utility Analysis of Therapy for Glaucoma: A Pilot Study for Republic of North Macedonia

    Jan 1, 2022, 00:00

  • POSB322 The Goal Attainment Scaling Method Is Robust to Violations of Normality in Goal Scales: A Simulation Study

    Jan 1, 2022, 00:00

  • Methodological Developments in Network Meta-Analysis and Comparative Effectiveness Research

    Jan 1, 2022, 00:00

  • POSB377 Preliminary Psychometric Evaluation of the Respiratory Syncytial Virus Infection Intensity Impact Questionnaire (RSV-IIIQ) in Adults

    Jan 1, 2022, 00:00

  • POSB431 Patient Preferences in the Management of Wet Age-Related Macular Degeneration: A Conjoint Analysis

    Jan 1, 2022, 00:00

  • POSA312 Exploring Health Related Factors Indicating Susceptibility to COVID19

    Jan 1, 2022, 00:00

  • POSB327 Assessing the Benefits of Improving Health-Related Quality of Life in Heart Failure: A Preliminary Analysis in EU, UK, and Canada

    Jan 1, 2022, 00:00

  • POSA382 Evaluating the Quality of Health-State Utilities in Cost-Utility Analyses in Asia

    Jan 1, 2022, 00:00

  • POSB321 Assessment of the Relationship between Collision Rate and Sample Size Using a Large US Mortality Dataset

    Jan 1, 2022, 00:00

  • POSA428 The Impact of Treatment Effect Parameterization in Mixture Cure Models on Survival Estimates and Uncertainty

    Jan 1, 2022, 00:00

  • POSC314 Indirect Treatment Comparison: A Proposed Decision Algorithm to Define the Best Approach

    Jan 1, 2022, 00:00

  • POSB63 Analysis of Cost per PASI75 and per Dlqi 0/1 Responder over 52 WEEKS in Patients with Moderate Plaque Psoriasis Initiated on Apremilast, Remaining on Apremilast or Switching to Biologics, and Patients Hypothetically Treated with Biol ...

    Jan 1, 2022, 00:00

  • POSB421 A Framework for Expert Elicitation Related to Counterfactual Values: A Case Study of Elicitation to Inform Subgroup Analyses in Clinical Trials.

    Jan 1, 2022, 00:00

  • POSB350 Real-World (RW) Patient-Reported Outcomes (PROs) in Frontline Maintenance Therapy for Advanced Non-Small Cell Lung Cancer (aNSCLC) in France, Germany, and the UK

    Jan 1, 2022, 00:00

  • POSC195 What Is the Burden of Varicella-Associated Complications: A Systematic Literature Review

    Jan 1, 2022, 00:00

  • POSB268 Landscape Review Exploring Acceptability of Oncology Surrogate Endpoints By NICE (England), CADTH (Canada), and PBAC (Australia) from 2010 to 2021

    Jan 1, 2022, 00:00

  • POSB336 Comparative Study of Movement Patterns and Development During a 6-Week Training Programme for Triathletes and Orienteerers

    Jan 1, 2022, 00:00

  • POSC179 Risk Factors for Pneumococcal Disease in Persons with Chronic Medical Conditions: Life Study

    Jan 1, 2022, 00:00

  • POSB228 Clinical Effectiveness of Facility Based Interventions to Improve Uptake of Dual Contraception Among Women Living with HIV: A Systematic Review and Meta Analysis

    Jan 1, 2022, 00:00

  • POSB168 The Burden of Atopic Dermatitis in Adults and Adolescents: A Systematic Literature Review

    Jan 1, 2022, 00:00

  • POSB418 Management of Patients with Deficiency of Adenosine Deaminase 2 (DADA2): A Systematic Literature Review

    Jan 1, 2022, 00:00

  • POSC323 Improving a Rating Scale: Applying Rasch Analysis to Student Pharmacists′ Perceptions of Their Professional Identity

    Jan 1, 2022, 00:00

  • Access to Care/Real World Evidence to Inform Decision Making

    Jan 1, 2022, 00:00

  • POSA239 Impact of AIFA Note 96 on Vitamin D Analogs' Prescriptive Appropriateness

    Jan 1, 2022, 00:00

  • Comparing Modeling Approaches for Discrete Event Simulations With Competing Risks Based on Censored Individual Patient Data: A Simulation Study and Illustration in Colorectal Cancer [Editor's Choice]

    Jan 1, 2022, 00:00

  • POSC72 Clinical and Cost Effectiveness of a Clinic-Based and Two Digital Applications of McKenzie Therapy for Chronic Low-Back Pain

    Jan 1, 2022, 00:00

  • POSC238 Real World Data of Acute Pain Prescription in a Health District

    Jan 1, 2022, 00:00

  • POSC411 Multi-State Modelling Accurately Characterises the Persistence to Distinct Preventive Treatment Lines in Migraine Patients

    Jan 1, 2022, 00:00

  • POSC360 The Patient Perspective on Achieving Near Normoglycemia in People with Type 2 Diabetes

    Jan 1, 2022, 00:00

  • POSC325 Use of the New French ‘Organizational Impact Map’ Published by the Haute Autorité de Santé (HAS) to Evaluate the Organizational Impact of Immune-Checkpoint Inhibitors in Advanced Cancers

    Jan 1, 2022, 00:00

  • POSC46 A Cost-Effectiveness Analysis of Patiromer for the Treatment of Hyperkalemia in Spain

    Jan 1, 2022, 00:00

  • POSA123 Does Indication Expansion Automatically Lead to Price Erosion in France/Germany for Orphan and Oncology Drugs?

    Jan 1, 2022, 00:00

  • POSC271 NHS England: How Important Is This Emergent Stakeholder in UK Market Access?

    Jan 1, 2022, 00:00

  • POSA1 COA Development and Evaluation in Rare Disease: A Narrative Review

    Jan 1, 2022, 00:00

  • POSA342 Reported Utilities and Health-Related Quality of Life (HRQOL) Data for Patients with Muscle Invasive Urothelial Carcinoma (MIUC) Treated with Radical Resection (RR): A Systematic Literature Review (SLR)

    Jan 1, 2022, 00:00

  • POSC183 Epidemiological Disease Burden of Malignant Neoplasm of Oropharynx Based on Routinely Collected Health Insurance Claims Data

    Jan 1, 2022, 00:00

  • POSA317 Comparison of Caregiver Inter-Rater Agreement and Test-Retest Reliability on the Infant with Clefts Observation Outcomes Instrument (ICOO): Implications for Clinical Trials

    Jan 1, 2022, 00:00

  • POSA64 The Life-Long Economic Burden of Immunoglobulin A Nephropathy (IGAN) in China

    Jan 1, 2022, 00:00

  • POSC254 The Impact of COVID-19 on European HTA Decisions

    Jan 1, 2022, 00:00

  • P15 Transcatheter versus Surgical Aortic Valve Replacement: A Real-World Comparison of Clinical Outcomes Based on a German Claims Dataset

    Jan 1, 2022, 00:00

  • POSC262 Exploring Health Technology Assessment (HTA) Acceptance of Disease-Free Survival (DFS) as an Appropriate Endpoint in Early-Stage, Non-Metastatic Solid Tumours

    Jan 1, 2022, 00:00

  • POSC299 Transportability Analysis: A Principled Method for Transporting Treatment Effects Observed in One Real-World Dataset to Another

    Jan 1, 2022, 00:00

  • P24 Telehealth Access and Use by the U.S. Medicare Population during the Pandemic

    Jan 1, 2022, 00:00

  • POSB10 Identification of Medication-Related Problems Among RURAL Community-Dwelling Patients Receiving Telephonic Medication Therapy Management Services

    Jan 1, 2022, 00:00

  • POSB373 Translation and Cross-Cultural Adaptation of the Decisional Conflict Scale for Its Use in Migraine Patients in Spain

    Jan 1, 2022, 00:00

  • POSB316 Extending the Hierarchical Decision Matrix to Incorporate a Dominance Ranking Score for Economic Systematic Reviews

    Jan 1, 2022, 00:00

  • P31 Impact of COVID-19 on HTA/PRMA of Medicinal Products in Europe: A Payer Perspective

    Jan 1, 2022, 00:00

  • POSA321 Estimating Correlations Between Relative Efficacy of Immuno-Oncology Monotherapies Across Four Oncology Indications

    Jan 1, 2022, 00:00

  • POSC417 Hospital Administrative Data to Identify NSCLC: An Algorithm Evaluation Study

    Jan 1, 2022, 00:00

  • POSC62 Prescription Patterns and Trends of Hepatoprotective Medicines in Japan: A Health Insurance Claims Database Analysis

    Jan 1, 2022, 00:00

  • POSA90 Annual Health Insurance Treatment Cost of Left Ventricular Failure Based on Routinely Collected Financing Data

    Jan 1, 2022, 00:00

  • POSC290 The Monitor Intervene Predict (MIP) Value Framework: A Structured Approach to Measuring How Digital Health Can Improve Health Outcomes and Reduce Burden of Illness

    Jan 1, 2022, 00:00

  • POSA98 Carbon Footprint and Associated Costs of Asthma Exacerbation Care Among UK Adults

    Jan 1, 2022, 00:00

  • POSB202 Epidemiology and Clinical Management of Patients with Methotrexate Toxicity in Spain Using the Delphi Technique

    Jan 1, 2022, 00:00

  • POSC134 Cost-Effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer

    Jan 1, 2022, 00:00

  • POSA147 A Review of Methods Used to Estimate Pediatric Utility Values in Health Technology Appraisals Across Different Agencies

    Jan 1, 2022, 00:00

  • POSC81 Cost-Effectiveness Analysis of Once-Daily Insulin Glargine 300 U/mL (Gla-300) vs Insulin Degludec (IDeg-100) Using the BRAVO Diabetes Model

    Jan 1, 2022, 00:00

  • POSB191 Modeled Impact of Nirsevimab Against Respiratory Syncytial Virus (RSV) Among French Infants Experiencing Their First RSV Season

    Jan 1, 2022, 00:00

  • POSC322 The Impact of Treatment Coefficient Parameterization for Mixture Cure Models on Cost-Effectiveness Models

    Jan 1, 2022, 00:00

  • POSA14 The Role of Localization in Linguistic Validation (LV)

    Jan 1, 2022, 00:00

  • POSB261 Cancer Patients’ Willingness to Pay per Quality-Adjusted Life Year in ASIA-Pacific: A Systematic Review and Correlation Analysis with Population Metrics

    Jan 1, 2022, 00:00

  • POSB28 Comparative Effectiveness of Treatments for Advanced or Metastatic Triple Negative Breast Cancer (TNBC) Patients: A Systematic Review and Network Meta-Analysis

    Jan 1, 2022, 00:00

  • POSA71 Cost-Effectiveness of NT-PRO-BNP in Patients with Chronic Heart Failure with or without Type 2 Diabetes Mellitus in Austria

    Jan 1, 2022, 00:00

  • Using Real World Data to Assess Patient Outcomes

    Jan 1, 2022, 00:00

  • POSA253 Effect of Pharmacist Care on Clinical Outcomes Among People Living with HIV/AIDS: A Systematic Review and Meta-Analysis

    Jan 1, 2022, 00:00

  • POSA281 Phytotherapy for Women with Uncomplicated Recurrent Urocystitis

    Jan 1, 2022, 00:00

  • POSC396 Real-World Treatment Pattern and Direct Medical Costs of Atopic Dermatitis in China: A Retrospective Claims Database Analysis

    Jan 1, 2022, 00:00

  • POSA210 Decentralized Study Methods: A Summary of the Regulatory Landscape in the SARS-COV-2 Era and Beyond

    Jan 1, 2022, 00:00

  • POSA189 Epidemiological Disease Burden of Hypertensive Heart and Chronic Kidney Disease with Heart Failure Based on Routinely Collected Health Insurance Claims Data

    Jan 1, 2022, 00:00

  • POSB158 Cost-Effectiveness of Obinutuzumab Combined with Chemotherapy As Induction Therapy and Followed By Obinutuzumab Maintenance Therapy for Treatment Naïve Patients with Advanced Follicular Lymphoma in Mainland China

    Jan 1, 2022, 00:00

  • POSB269 The Use of External Data to Inform Survival Extrapolation in Oncology Technology Appraisals: A Comprehensive Review

    Jan 1, 2022, 00:00

  • POSB72 Subcutaneous Daratumumab in the Treatment of Multiple Myeloma in Italy: A Budget Impact Analysis

    Jan 1, 2022, 00:00

  • POSC236 Atopic Dermatitis: Trends in Real-World Treatment Patterns in Dermatology Specialty Networks

    Jan 1, 2022, 00:00

  • The Optimal Sample Size for Usability Testing, From the Manufacturer’s Perspective: A Value-of-Information Approach

    Jan 1, 2022, 00:00

  • POSB25 Public Health Benefit of Switching to High Dose Quadrivalent Vaccine for Influenza Seasonal Vaccination in Portuguese Elderly Population.

    Jan 1, 2022, 00:00

  • POSA392 Opera Study: Observatory of a Population Eligible to a Reintervention of a Bariatric Surgery in France- Impact of the Different Revisional Bariatric Surgeries on Diabetes Mellitus and Its Treatments.

    Jan 1, 2022, 00:00

  • POSC206 How Gene Therapy for Rare Diseases Differs from Chronic Therapy: The Case of AADC-Deficiency

    Jan 1, 2022, 00:00

  • POSB132 Ferric Carboxymaltose for the Treatment of Iron Deficiency in Patients with Acute Heart Failure with Reduced Ejection Fraction: Events Avoided and Cost Savings from the Perspective of Healthcare Payers in the United States

    Jan 1, 2022, 00:00

  • POSC27 Comparing Length of Stay of Open, Video-Assisted Thoracoscopic, and Robot-Assisted Lobectomy in Japan

    Jan 1, 2022, 00:00

  • POSC124 Economic Burden of Antimicrobial Resistan An Analysis of the Additional Bed Day Costs Associated with Treating Resistant Infections in Ireland

    Jan 1, 2022, 00:00

  • POSC208 The Value-Based Contracting Cookbook: A Recipe for Successful Implementation

    Jan 1, 2022, 00:00

  • POSA324 How General Practitioners in India Take on the Clinical Pharmacists Advice on the Rational Prescribing of Antibiotics: A Cross-Sectional Evaluation

    Jan 1, 2022, 00:00

  • POSB196 Epidemiology of Osteoporosis: Risk Factor Distribution, Osteoporosis Prevalence and Treatment Gap in the General Population ≥50 Years of Age in Germany

    Jan 1, 2022, 00:00
  • «
  • 41
  • 42
  • 43
  • 44 (current)
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • »